EP12.01. Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC - PDF(Slides)
Back to course
Pdf Summary
Asset Subtitle
Nir Peled
Meta Tag
Speaker Nir Peled
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
Keywords
amivantamab
salvage therapy
EGFR-mutated non-small cell lung cancer
disease progression
EGFR TKIs
osimertinib
mobocertinib
objective response rate
progression-free survival
grade 3 toxicity
Powered By